Movement Alert｜Twist Bioscience Rises 5.41% in Regular Trading, Accelerating Beyond Investment Bank Target Price of $90

Market Focus06-26 22:37

On June 26, Twist Bioscience rose 5.41% in regular trading, trading at $101.81/share, with turnover of $60.94 million. The stock continued its accelerating upward trajectory after breaking through Canaccord Genuity's previously assigned $90 price target.

On the news front, the rally represents an extension of strong momentum following multiple analyst upgrades. Canaccord Genuity initiated coverage with a Buy rating and $90 price target, significantly above the market consensus target of $73.12. Earlier, Leerink Partners upgraded the stock to Outperform from Market Perform, raising its target to $70 from $55 following Q2 results that beat sales guidance. The company guided fiscal Q3 revenue of $114M-$115M versus the FactSet estimate of $111.3M, and raised full-year sales guidance to $435M-$440M. Management also projected adjusted EBITDA breakeven by fiscal Q4. Dilution concerns from a $200 million shelf registration filed on June 19 initially caused a pullback, but market sentiment quickly recovered as bullish analyst coverage provided strong support.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1140965725?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-26 22:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1140965725","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Twist Bioscience Rises 5.41% in Regular Trading, Accelerating Beyond Investment Bank Target Price of $90","media":"Market Focus","content":"<p><p>On June 26, Twist Bioscience rose 5.41% in regular trading, trading at $101.81/share, with turnover of $60.94 million. The stock continued its accelerating upward trajectory after breaking through Canaccord Genuity's previously assigned $90 price target.</p><p>On the news front, the rally represents an extension of strong momentum following multiple analyst upgrades. Canaccord Genuity initiated coverage with a Buy rating and $90 price target, significantly above the market consensus target of $73.12. Earlier, Leerink Partners upgraded the stock to Outperform from Market Perform, raising its target to $70 from $55 following Q2 results that beat sales guidance. The company guided fiscal Q3 revenue of $114M-$115M versus the FactSet estimate of $111.3M, and raised full-year sales guidance to $435M-$440M. Management also projected adjusted EBITDA breakeven by fiscal Q4. Dilution concerns from a $200 million shelf registration filed on June 19 initially caused a pullback, but market sentiment quickly recovered as bullish analyst coverage provided strong support.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Twist Bioscience Rises 5.41% in Regular Trading, Accelerating Beyond Investment Bank Target Price of $90</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Twist Bioscience Rises 5.41% in Regular Trading, Accelerating Beyond Investment Bank Target Price of $90\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-26 22:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 26, Twist Bioscience rose 5.41% in regular trading, trading at $101.81/share, with turnover of $60.94 million. The stock continued its accelerating upward trajectory after breaking through Canaccord Genuity's previously assigned $90 price target.</p><p>On the news front, the rally represents an extension of strong momentum following multiple analyst upgrades. Canaccord Genuity initiated coverage with a Buy rating and $90 price target, significantly above the market consensus target of $73.12. Earlier, Leerink Partners upgraded the stock to Outperform from Market Perform, raising its target to $70 from $55 following Q2 results that beat sales guidance. The company guided fiscal Q3 revenue of $114M-$115M versus the FactSet estimate of $111.3M, and raised full-year sales guidance to $435M-$440M. Management also projected adjusted EBITDA breakeven by fiscal Q4. Dilution concerns from a $200 million shelf registration filed on June 19 initially caused a pullback, but market sentiment quickly recovered as bullish analyst coverage provided strong support.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TWST","symbol_name":"Twist Bioscience Corp","start_time":0,"source_url":"","article_id":"1140965725","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1140965725","pubTimestamp":1782484620,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 26, Twist Bioscience rose 5.41% in regular trading, trading at $101.81/share, with turnover of $60.94 million. The stock continued its accelerating upward trajectory after breaking through...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TWST":"Twist Bioscience Corp"},"translate_title":"动向提示|Twist Bioscience常规交易涨5.41%加速突破投行目标价90美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TWST":1},"content_text":"On June 26, Twist Bioscience rose 5.41% in regular trading, trading at $101.81/share, with turnover of $60.94 million. The stock continued its accelerating upward trajectory after breaking through Canaccord Genuity's previously assigned $90 price target.On the news front, the rally represents an extension of strong momentum following multiple analyst upgrades. Canaccord Genuity initiated coverage with a Buy rating and $90 price target, significantly above the market consensus target of $73.12. Earlier, Leerink Partners upgraded the stock to Outperform from Market Perform, raising its target to $70 from $55 following Q2 results that beat sales guidance. The company guided fiscal Q3 revenue of $114M-$115M versus the FactSet estimate of $111.3M, and raised full-year sales guidance to $435M-$440M. Management also projected adjusted EBITDA breakeven by fiscal Q4. Dilution concerns from a $200 million shelf registration filed on June 19 initially caused a pullback, but market sentiment quickly recovered as bullish analyst coverage provided strong support.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1140965725","isCrawlerRequest":true}